Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00594308 · ClinicalTrials.gov registry record · NA
In-Vivo Activated T-Cell Depletion to Prevent GVHD
A NA study, sponsored by Indiana University.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00594308 is a NA study that was terminated before completion, run by Indiana University. The registered enrollment target is 10 participants.
The verdict
NCT00594308, a NA study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of graft-versus-host disease. This research is being done because there is no completely safe and effective prevention for graft-versus-host disease. It is known that cyclosporine helps with GVHD but we would like to know if the addition of basiliximab will decrease the incidence and/or severity of GVHD after a transplant known as nonmyeloablative ("mini" transplant).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Cyclosporine
- DRUG Mycophenolate mofetil
- DRUG Basiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00594308
The ClinicalTrials.gov registry entry for NCT00594308 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00594308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00594308 about?
NCT00594308 is a clinical study titled "In-Vivo Activated T-Cell Depletion to Prevent GVHD". The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of graft-versus-host disease. This research is being done because there is no completely safe and effective prevention for gra...
What is the current status of trial NCT00594308?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2007-10.
What interventions are being tested in trial NCT00594308?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Cyclosporine (DRUG), Mycophenolate mofetil (DRUG), Basiliximab (DRUG).
Who is sponsoring clinical trial NCT00594308?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.